{"generic":"Mepenzolate Bromide","drugs":["Cantil","Mepenzolate Bromide"],"mono":{"0":{"id":"368110-s-0","title":"Generic Names","mono":"Mepenzolate Bromide"},"1":{"id":"368110-s-1","title":"Dosing and Indications","sub":[{"id":"368110-s-1-4","title":"Adult Dosing","mono":"<b>Peptic ulcer disease; Adjunct:<\/b> 25 to 50 mg ORALLY 4 times daily with meals and at bedtime; begin with lowest dose and adjust based on clinical response "},{"id":"368110-s-1-5","title":"Pediatric Dosing","mono":"safety and efficacy have not been established in pediatric patients "},{"id":"368110-s-1-6","title":"Dose Adjustments","mono":"<b>Geriatric:<\/b> begin at the low end of the dosing range and titrate carefully "},{"id":"368110-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Peptic ulcer disease; Adjunct<br\/>"}]},"3":{"id":"368110-s-3","title":"Contraindications\/Warnings","sub":[{"id":"368110-s-3-9","title":"Contraindications","mono":"<ul><li>acute gastrointestinal hemorrhage with unstable cardiovascular status<\/li><li>allergic or idiosyncratic reactions to mepenzolate or related agents<\/li><li>gastrointestinal obstructive disease (eg, pyloroduodenal stenosis, achalasia)<\/li><li>glaucoma<\/li><li>intestinal atony of the elderly or debilitated<\/li><li>myasthenia gravis<\/li><li>obstructive uropathy<\/li><li>paralytic ileus<\/li><li>ulcerative colitis complicated by toxic megacolon<\/li><\/ul>"},{"id":"368110-s-3-10","title":"Precautions","mono":"<ul><li>Cardiovascular:<\/li><li>-- congestive heart failure<\/li><li>-- cardiac arrhythmias<\/li><li>-- coronary heart disease<\/li><li>-- hypertension<\/li><li>-- tachycardia; evaluate prior to administration; exacerbation may occur<\/li><li>Neurologic:<\/li><li>-- autonomic neuropathy<\/li><li>Endocrine\/Metabolic:<\/li><li>-- decreased sweating may result in heat prostration, including heat stroke and fever, when environmental temperatures are high<\/li><li>-- hyperthyroidism<\/li><li>Gastrointestinal:<\/li><li>-- diarrhea may be an early symptom of incomplete gastrointestinal obstruction (inappropriate use), especially in patients with ileostomy or colostomy<\/li><li>-- gastric ulcer therapy (off-label use); complications (antral statis) may occur due to delayed gastric emptying<\/li><li>-- hiatal hernia associated with reflux esophagitis<\/li><li>-- ulcerative colitis; large doses may suppress intestinal mobility leading to paralytic ileus and precipitation or aggravation of toxic megacolon<\/li><li>Hepatic:<\/li><li>-- hepatic disease<\/li><li>Immunologic:<\/li><li>-- allergic-type reactions may occur in tartrazine-sensitive patients, especially those who also have aspirin sensitivity<\/li><li>Ophthalmic:<\/li><li>-- blurred vision may occur<\/li><li>Other:<\/li><li>-- elderly; dose adjustment may be required<\/li><li>Psychiatric:<\/li><li>-- psychosis has been reported<\/li><li>Renal:<\/li><li>-- renal disease<\/li><li>Reproductive:<\/li><li>-- prostatic hypertrophy<\/li><\/ul>"},{"id":"368110-s-3-11","title":"Pregnancy Category","mono":"Mepenzolate: B (FDA)<br\/>"},{"id":"368110-s-3-12","title":"Breast Feeding","mono":"Mepenzolate: Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"368110-s-4","title":"Drug Interactions","sub":{"1":{"id":"368110-s-4-14","title":"Major","mono":"<ul><li>Bupropion (theoretical)<\/li><li>Donepezil (theoretical)<\/li><li>Morphine (theoretical)<\/li><li>Morphine Sulfate Liposome (theoretical)<\/li><li>Oxymorphone (probable)<\/li><li>Umeclidinium (theoretical)<\/li><\/ul>"}}},"5":{"id":"368110-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Neurologic:<\/b>Somnolence<\/li><li><b>Ophthalmic:<\/b>Blurred vision<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Tachycardia<\/li><li><b>Endocrine metabolic:<\/b>Diminished sweating<\/li><li><b>Psychiatric:<\/b>Psychotic disorder<\/li><\/ul>"},"6":{"id":"368110-s-6","title":"Drug Name Info","sub":{"0":{"id":"368110-s-6-17","title":"US Trade Names","mono":"Cantil<br\/>"},"2":{"id":"368110-s-6-19","title":"Class","mono":"<ul><li>Antimuscarinic<\/li><li>Gastrointestinal Agent<\/li><\/ul>"},"3":{"id":"368110-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"368110-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"368110-s-7","title":"Mechanism Of Action","mono":"Mepenzolate bromide is a postganglionic parasympathetic inhibitor that decreases gastric acid and pepsin secretions and suppresses spontaneous colonic contractions.<br\/>"},"8":{"id":"368110-s-8","title":"Pharmacokinetics","sub":{"0":{"id":"368110-s-8-23","title":"Absorption","mono":"Bioavailability, Oral: low <br\/>"},"3":{"id":"368110-s-8-26","title":"Excretion","mono":"Renal: 3% to 22% over 5 days, with the majority appearing on day 1 <br\/>"}}},"9":{"id":"368110-s-9","title":"Administration","mono":"<b>Oral<\/b><br\/>give with meals and at bedtime <br\/>"},"10":{"id":"368110-s-10","title":"Monitoring","mono":"<ul><li>improvement in symptoms of peptic ulcers indicates efficacy.<\/li><li>tachycardia prior to administration; additional increase in heart rate may occur<\/li><\/ul>"},"11":{"id":"368110-s-11","title":"How Supplied","mono":"<b>Cantil<\/b><br\/>Oral Tablet: 25 MG<br\/>"},"13":{"id":"368110-s-13","title":"Clinical Teaching","mono":"<ul><li>Drug may impair heat regulation due to decreased sweating. Advise patient to use caution with activities leading to an increased core temperature, such as strenuous exercise, exposure to extreme heat, or dehydration<\/li><li>Patient should avoid driving or other activities that require clear vision until drug effects are realized.<\/li><li>Tell patient to report diarrhea, especially those with ileostomy or colostomy.<\/li><li> Counsel patient to report CNS symptoms (eg, psychosis, confusion, disorientation, short-term memory loss, euphoria, hallucinations, dysarthria, ataxia, fatigue, insomnia, agitation, lowered anxiety).<\/li><li>Side effects may include blurred vision, vomiting, nausea, constipation, loss of taste, bloating, dry mouth, dizziness, weakness, drowsiness, headache, urticaria, anaphylaxis, urinary hesitancy or retention, impotence, or lactation suppression.<\/li><li>Patient should not use antacids while taking this drug.<\/li><\/ul>"}}}